During the past several years, identifying HIF-1 inhibitors has become a novel strategy to treat CRC and many drugs are being evaluated in clinical trials due to the central role of HIF-1 in maintaining high glycolysis rates [307]. This evidence concerns the gene HIF1A and colorectal carcinoma.